• Loading metrics

A Genome-Wide RNAi Screen in Caenorhabditis elegans Identifies the Nicotinic Acetylcholine Receptor Subunit ACR-7 as an Antipsychotic Drug Target

  • Taixiang Saur,

    Affiliations: Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America

  • Sarah E. DeMarco,

    Affiliation: Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America

  • Angelica Ortiz,

    Affiliation: Department of Molecular Pathology, University of Texas–MD Anderson Cancer Center, Houston, Texas, United States of America

  • Gregory R. Sliwoski,

    Affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

  • Limin Hao,

    Affiliations: Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America

  • Xin Wang,

    Affiliations: Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America

  • Bruce M. Cohen,

    Affiliations: Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America

  • Edgar A. Buttner

    Affiliations: Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America, Department of Neurology, Harvard Medical School, Boston, Massachusetts, United States of America

A Genome-Wide RNAi Screen in Caenorhabditis elegans Identifies the Nicotinic Acetylcholine Receptor Subunit ACR-7 as an Antipsychotic Drug Target

  • Taixiang Saur, 
  • Sarah E. DeMarco, 
  • Angelica Ortiz, 
  • Gregory R. Sliwoski, 
  • Limin Hao, 
  • Xin Wang, 
  • Bruce M. Cohen, 
  • Edgar A. Buttner


We report a genome-wide RNA interference (RNAi) screen for Suppressors of Clozapine-induced Larval Arrest (scla genes) in Caenorhabditis elegans, the first genetic suppressor screen for antipsychotic drug (APD) targets in an animal. The screen identifies 40 suppressors, including the α-like nicotinic acetylcholine receptor (nAChR) homolog acr-7. We validate the requirement for acr-7 by showing that acr-7 knockout suppresses clozapine-induced larval arrest and that expression of a full-length translational GFP fusion construct rescues this phenotype. nAChR agonists phenocopy the developmental effects of clozapine, while nAChR antagonists partially block these effects. ACR-7 is strongly expressed in the pharynx, and clozapine inhibits pharyngeal pumping. acr-7 knockout and nAChR antagonists suppress clozapine-induced inhibition of pharyngeal pumping. These findings suggest that clozapine activates ACR-7 channels in pharyngeal muscle, leading to tetanus of pharyngeal muscle with consequent larval arrest. No APDs are known to activate nAChRs, but a number of studies indicate that α7-nAChR agonists may prove effective for the treatment of psychosis. α-like nAChR signaling is a mechanism through which clozapine may produce its therapeutic and/or toxic effects in humans, a hypothesis that could be tested following identification of the mammalian ortholog of C. elegans acr-7.

Author Summary

Clozapine is the most effective medication for treatment-refractory schizophrenia but produces toxic side effects such as agranulocytosis, metabolic syndrome, and developmental defects after exposure early in life. However, clozapine's molecular mechanisms of action remain poorly understood. In past studies, we showed that pharmacogenomic experiments in C. elegans identify novel signaling pathways through which clozapine exerts its biological effects. Here, we report the first genetic suppressor screen for antipsychotic (APD) drug targets in an animal and identify 40 suppressors of clozapine-induced larval arrest, including the α-like nicotinic acetylcholine receptor (nAChR) acr-7. We validate our RNAi result by showing that an acr-7 knockout suppresses clozapine-induced larval arrest and inhibition of pharyngeal pumping. Expression of a full-length translational acr-7::GFP (Green Fluorescent Protein) construct in the acr-7 mutant rescues suppression of these phenotypes. Clozapine-induced phenotypes are phenocopied by nAChR agonists and blocked by nAChR antagonists. The results suggest that clozapine induces these phenotypes through activation of the ACR-7 receptor. Recent studies have underscored the potential importance of nAChRs in the pathophysiology of schizophrenia. A clearer understanding of APD mechanisms would facilitate the design of improved drugs and may inform our understanding, not only of drug mechanisms, but also of disease pathogenesis.


Treatment of psychotic disorders has been hampered by the limited efficacy of currently available APDs and the toxic side effects of these drugs [1]. Clozapine is the most effective medication for treatment-refractory schizophrenia but produces toxic side effects such as agranulocytosis, metabolic syndrome, and developmental defects after exposure early in life [2][4]. The molecular mechanisms underlying the therapeutic and toxic side effects of clozapine and other APDs remain poorly understood [5], [6]. A better understanding of these mechanisms could facilitate the design of superior drugs and may inform our understanding, not only of drug mechanisms, but also of disease pathogenesis. For example, studies of antidepressant drug mechanisms have produced new insight into the important role of neurogenesis in depression itself [7], [8].

The genetic tools of invertebrate models offer new paradigms for drug discovery in schizophrenia [9], [10]. Pharmacogenetic experiments in Caenorhabditis elegans identify novel and important signal transduction pathways through which APDs exert their biological effects [11][14]. Large-scale genetic screens in C. elegans provide an unbiased approach to discover genetic targets of APDs, and such experiments are not possible in knockout or transgenic mice. Using such an unbiased approach, we identified a potential APD target with homology to human brain receptors.

We found that loss-of-function mutations in acr-7, which encodes a homolog of the human α-like nAChRs, suppressed both developmental and behavioral effects of clozapine. Our results indicated that clozapine likely activated the ACR-7 receptor, a novel observation that may be relevant to clinical drug effects. No known APDs have been previously demonstrated to activate nAChRs, and whether APDs might act by this mechanism is an important question. Recent studies in humans have underscored the potential importance of nAChRs in the pathophysiology of schizophrenia owing to: (1) the abnormal expression of nAChRs in post-mortem brains of schizophrenic patients; (2) the striking association between smoking (a nicotine delivery system) and schizophrenia; (3) the improved cognition seen in animals and humans with nicotine exposure; (4) the genetic association between the human α7-nAChR and schizophrenia; and (5) the potential efficacy of nAChR agonists as treatments for schizophrenia [15][17].


A chemical genetic screen for APD targets

To identify novel molecular mechanisms of action of APDs, we conducted a genetic suppressor screen for APD targets in an animal [18]. APDs cause larval arrest or developmental delay in C. elegans (Figure 1B). APDs inhibit pharyngeal pumping [12], [19], [20], indicating that the developmental phenotype has a neuromuscular basis. To identify potential APD targets, we performed a genome-wide RNAi screen for Suppressors of Clozapine-induced Larval Arrest (scla genes). Mutants that escaped clozapine-induced larval arrest grew to adulthood and were easily detected under a dissecting microscope (Figure 1B, [21]). The experimental design is outlined in Figure 1A and involved a primary RNAi screen in liquid culture followed by triplicate testing in agar wells. To ensure adequate knockdown of potential targets, we exposed animals to two rounds of RNAi and tested progeny in the second generation. We also employed the NL4256 rrf-3(pk1426) II strain, which is hypersensitive to RNAi and which improves detection of genes with postembryonic mutant phenotypes, to maximize recovery of neuronal genes [22].

Figure 1. A genome-wide RNAi screen for scla genes yielded the nAChR gene acr-7.

(A) Experimental design of the feeding RNAi screen in liquid culture. On day 1, rrf-3 animals were synchronized, and bacteria was cultured from the Ahringer RNAi feeding library. Synchronized L1 animals were added to induced cultures on day 2 and were allowed to grow to adulthood for 3 days. Clozapine was added on day 5, and progeny were allowed to develop for 3 days. Progeny were scored for the Scla phenotype on day 8. (B1) N2 animals grew to adulthood within 3 days in the presence of 0.1% DMSO alone. (B2) 320 µM clozapine caused larval arrest in N2 animals exposed to feeding RNAi bacteria with empty vector alone. (B3) acr-7(RNAi) animals in 0.1% DMSO alone displayed normal development. (B4) acr-7(RNAi) suppressed developmental delay caused by 320 µM clozapine. (B5) The acr-7(tm863) knockout suppressed developmental delay caused by 320 µM clozapine. Note that experiments depicted in (B) were performed on NGM plates, not in liquid culture, to allow clear photographs.

Of the 19,968 wells we tested in the primary screen, 1,375 wells or 6.9% displayed suppression of clozapine-induced larval arrest. magi-1, a membrane-associated guanylate kinase gene, and sec-8 , an exocyst complex gene, were each identified as positives twice in the primary screen. Subsequent testing of primary screen positives in triplicate identified 40 candidate suppressors, constituting 0.2% of the total wells screened (Table 1). To rule out false positives, we collected viable knockout mutants corresponding to our RNAi suppressors and tested them for suppression of clozapine-induced larval arrest. These knockouts included strains acr-7(tm863), cep-1(ep347), cep-1(gk138), cep-1(lg12501), gtl-2(n2618), gtl-2(tm1463), ina-1(gm39), ins-22(ok3616), lron-6(ok1119), magi-1(gk657), puf-6(ok3044), scla-1(tm4534), scla-1(tm4806), and sms-1(ok2399). Suppression of clozapine-induced larval arrest was seen in 70% of the RNAi screen positives when tested by knockout rather than by RNAi knockdown, including acr-7, gtl-2, ina-1, magi-1, puf-6, sms-1, and scla-1. The cep-1, ins-22, and lron-6 knockout strains failed to suppress clozapine-induced larval arrest, suggesting that these suppressors were false positives. Alternatively, suppression may occur in these three cases with partial loss-of-function by RNAi knockdown, but not with complete loss-of-function by knockout.

Chemicals such as paraquat are commonly used to study the genetics of stressor-induced developmental delay or lethality in C. elegans. We asked whether genes recovered in our RNAi screen suppress the effects of stressors, including paraquat, DTT, SDS, and tunicamycin [23][26]. Tunicamycin up to 10 µg/ml and DTT at 5 mM produced no or mild developmental delay in N2 animals (data not shown). More robust effects were seen with 0.01% SDS or 0.2–0.5 mM paraquat (Figure S1). Developmental delay in N2 animals was compared with that in sms-1(ok2399), age-1(hx546), scla-1(tm4806), scla-1(tm4534), and acr-7(tm863) mutant strains. None of these mutant strains grew more rapidly in the presence of SDS or paraquat than N2 animals, suggesting that these mutations did not act by suppressing stressor effects (Figure S1). Rather, the suppression seen with these mutations appeared to be specific for the developmental effects of clozapine. Stressor-induced lethality was also scored, and, similar to the results of the developmental delay assay, no suppression was seen with these mutations (data not shown).

The functional classes of the suppressors revealed that a more diverse group of genes was required for the biological effects of clozapine than had been previously appreciated. A fraction of these genes likely suppressed clozapine-induced larval arrest via indirect effects. However, molecules involved in signal transduction significantly outnumbered those in other functional classes, consistent with the idea that clozapine's developmental effects have a neuromuscular basis (Figure 2, [12], [19]). Moreover, the fraction of signal transduction genes from our RNAi screen was higher than that from a screen for all genes with RNAi phenotypes in C. elegans [27]. This difference indicated that our dataset was specific to the effects of clozapine.

Figure 2. Functional diversity of scla genes.

Genes were classified by biological process based on Gene Ontology terms from Wormbase. The percentages for each functional class of genes required for suppression of clozapine-induced larval arrest are shown.

acr-7 sequence and homology

We sought to understand the molecular mechanisms of action of the RNAi suppressors in detail and chose to focus initially on acr-7. The rationale for focusing on acr-7, as opposed to other new candidate APD targets, included potential relevance to psychotic disorders [15][17], probability of a human ortholog [28], [29], and potential for physiological characterization [30]. Blasting the ACR-7 protein sequence against the human genome using Wormbase BLAT revealed that ACR-7 is homologous to a number of human α-like nAChRs, but which human gene is the true acr-7 ortholog is not known. Homology comparisons with the human α7-nAChR showed 36% identity overall and greater identity within the first two predicted transmembrane domains of the ion channel (Figure 3A). The pore-lining transmembrane domain II (M2) and neighboring residues play an important role in the ion selectivity filter of nAChRs. Specifically, substitution of the glutamate residue immediately preceding M2 or the glutamate residue at the extracellular mouth of the pore significantly reduces the calcium permeability of various nAChR subunits [31]. We noted that both glutamate residues are conserved in ACR-7, suggesting that, like the human α7-nAChR, ACR-7 is highly permeable to calcium. Our attempts to obtain voltage-clamp recordings of ACR-7 expressed in heterologous systems, including Xenopus laevis oocytes and cultured HEK293T and PC12 cells, failed, consistent with the possibility that ACR-7 is a subunit of a heteromeric channel [32], [33].

Figure 3. ACR-7 protein sequence alignment and acr-7 gene structure.

(A) The C. elegans ACR-7 protein and human α7-nAChR subunit CHRNA7 were aligned using ClustalW. The four putative transmembrane domains, as predicted for the human CHRNA7 protein, were boxed. nAChRs are members of the cys-loop family of ionotropic neurotransmitter receptors, and this conserved di-cysteine loop is dotted line-boxed. α-nAChR subunits contain a pair of vicinal cysteines within the Ach binding site, and these residues are marked with asterisks. The C. elegans and human proteins share 36% identity overall and 41% identity within the pore-lining transmembrane domain II (M2). (B) The acr-7 gene contains 13 exons, and the region deleted in the tm863 allele is marked with a line. tm863 is an out-of-frame deletion which removes exons 6–7 and most of exons 5 and 8. (C) The tm863 knockout is predicted to lack all four transmembrane domains and to be a null allele.

Knockout of acr-7 suppressed clozapine-induced larval arrest

We tested growth effects over a range of clozapine concentrations (40–320 µM). N2 animals grown in the presence of 0.1% DMSO alone reached adulthood in ∼3 days (Figure 1B and Figure 4A). Consistent with our previous study [12], clozapine inhibited the development of N2 animals in a dose-dependent fashion. For example, 98% of control animals were gravid adults on day 3, compared to 36% on 80 µM clozapine and 0% on 320 µM clozapine (Figure 1B and Figure 4A).

Figure 4. Genetic and pharmacological characterization of clozapine-induced larval arrest.

(A) Clozapine induced developmental delay in wild-type C. elegans in a concentration-dependent manner. acr-7(tm863) partially suppressed this developmental delay, and the suppression was rescued by expression of ACR-7 in the mutant background. Expression was driven by a putative acr-7 promoter in the case of acr-7(tm863) mchEx40 or by the pharyngeal muscle-specific myo-2 promoter in the case of acr-7(tm863) mchEx207. Growth was measured as the percentage of different development stages 72 hours after loading synchronized L1 animals into the drug plates. Different concentrations (80, 160, 320 µM) of clozapine were dissolved in DMSO with the maximum concentration of DMSO being 0.1%. 0.1% DMSO alone was used for control wells. (B) nAChR agonists nicotine (Nico) and levamisole (Leva) induced developmental delay in a concentration-dependent manner, mimicking the effect of clozapine. (C) Nicotine-induced developmental delay is suppressed by acr-7(tm863), and suppression was partially rescued by expression of full-length ACR-7 in the mutant background. (D) Nicotine receptor antagonists d-TC (100 and 500 µM) and DHβE (100 and 500 µM) suppressed clozapine (Cloz)-induced developmental delay. d-TC or DHβE alone did not affect the growth of the animals at 100 and 500 µM.

The acr-7(tm863) allele is a 625 bp out-of-frame deletion with a 7 bp insertion, which removes exons 6–7 and most of exons 5 and 8 (Figure 3B) and lacks all four transmembrane domains (Figure 3C). Therefore, acr-7(tm863) is predicted to be a null allele. We backcrossed the acr-7(tm863) allele to the wild-type strain six times to generate the strain EAB200, which, like animals exposed to acr-7(RNAi) (Figure 1B), displayed normal development and normal adult morphology. On 320 µM clozapine, 95% of acr-7(tm863) mutant animals reached the L4 and young adult (YA) stages by day 3, compared to 0% of N2 animals (Figure 1B and Figure 4A). Therefore, acr-7(tm863) partially suppressed clozapine-induced developmental delay, confirming the knockdown results from our RNAi screen. Transgenic strain acr-7(tm863) II mchEx40, which expresses a full-length translational Pacr-7::acr-7::GFP (Green Fluorescent Protein) fusion construct, was rescued for the Scla phenotype. On 320 µM clozapine, 100% of these transgenic animals were arrested at early larval stages (L1, L2, and L3) on day 3, comparable to the delay seen in N2 animals (Figure 4A). We investigated the specificity of acr-7(lf) suppression by testing mutations in 21 other C. elegans nAChR subunits and found that only acr-7(lf) suppressed clozapine-induced developmental delay (Figure 5).

Figure 5. Suppression by acr-7(lf) is specific.

A series of 22 nAChR mutants were tested for suppression of clozapine-induced larval arrest, and only acr-7(lf) produced robust suppression.

Developmental effects of nAChR agonists and antagonists

To determine the mechanism of action of clozapine, we tested the nAChR agonists nicotine and levamisole [29] and found that they inhibited growth in a dose-dependent fashion, phenocopying the effects of clozapine. Only 3% of N2 animals grew to young adults or beyond by day 3 on 1 mM nicotine, compared to 100% of control animals (Figure 4B). On 10 mM levamisole, all N2 animals were arrested at the L1–L2 stages on day 3 (Figure 4B). Similar to its suppression of clozapine-induced developmental delay, the acr-7(tm863) mutation suppressed nicotine-induced developmental delay (Figure 4C). This suppression was partially rescued in acr-7(tm863) II mchEx40 animals (Figure 4C). We also found that clozapine-induced larval arrest was blocked by the nAChR antagonists d-tubocurarine (d-TC) and dihydro-beta-erythroidine (DHβE) [29]. In 320 µM clozapine alone, 96% of N2 animals were arrested at the L1–L2 stages on day 3, compared to 25% in the presence of 500 µM d-TC and 41% in the presence of 500 µM DHβE (Figure 4D). N2 animals displayed normal development in the presence of d-TC or DHβE alone, consistent with the normal development seen with acr-7 knockdown or knockout (Figure 4D). Taken as a whole, our results were consistent with the notion that acr-7 encodes a nAChR and that clozapine activates ACR-7. Suppression of the developmental effects of clozapine and nicotine are the first phenotypes to be identified in acr-7 mutants [34].

Mutations in cha-1 or unc-17 failed to suppress clozapine-induced larval arrest

Our results did not exclude the possibility that clozapine might activate ACR-7 by triggering release of acetylcholine (Ach). If clozapine does so, then mutations in genes required for Ach release should have suppressed clozapine-induced developmental delay. We tested two alleles of the choline acetyltransferase gene cha-1 and two alleles of the synaptic vesicle Ach transporter gene unc-17 for suppression of clozapine-induced developmental delay [35], [36]. Although both genes are required for Ach release, we found that mutations in cha-1 or unc-17 were not suppressors, suggesting that clozapine did not cause developmental delay by stimulating Ach release (Figure 6).

Figure 6. Ach release was not the mechanism of clozapine-induced larval arrest.

Mutations in genes required for Ach release failed to suppress clozapine-induced developmental delay. Strong loss-of-function of the choline acetyltransferase gene cha-1 or the synaptic vesicle Ach transporter gene unc-17 alone produced developmental delay. Therefore, both weak (n2411 or e113) and strong (p1152 or e245) loss-of-function alleles were tested.

acr-7 was expressed in pharyngeal muscle

We generated transgenic lines expressing a Pacr-7::GFP transcriptional fusion construct or a Pacr-7::acr-7::GFP translational fusion construct. In both cases, GFP was strongly expressed in the pharyngeal muscles of transgenic animals (Figure 7A). Using pharyngeal pumping and fluorescent bead assays, we previously showed that clozapine caused dose-dependent inhibition of pharyngeal pumping [12]. Inhibition of pharyngeal pumping causes larval arrest in C. elegans [37]. Thus, clozapine likely delayed development, in part, by inhibiting pharyngeal pumping.

Figure 7. ACR-7 acted in the pharyngeal muscle.

(A) ACR-7 was highly expressed in the pharynx as indicated by the arrows. A, anterior; P, posterior; D, dorsal; V, ventral. Scattered expression was also observed in the tail and vulval regions. (B) Clozapine inhibited pharyngeal pumping in wild-type animals in a concentration-dependent manner. Suppression of clozapine-induced inhibition of pharyngeal pumping was seen in acr-7(tm863) animals, and rescue was observed with expression of ACR-7 in the mutant background. A putative acr-7 promoter was utilized to drive expression for the acr-7(tm863) mchEx40 strain, whereas the pharyngeal muscle-specific myo-2 promoter was utilized for the acr-7(tm863) mchEx207 strain. (C) Both nicotine and clozapine inhibited the pumping rate in N2 animals. d-TC partially blocked these effects. Importantly, d-TC alone had no effect on pumping. (D) d-TC failed to block clozapine- or nicotine-induced inhibition of pumping in acr-7(lf) animals. * P<0.05; ** P<0.01; *** P<0.0001.

What is the mechanism by which clozapine inhibited pharyngeal pumping? The C. elegans pharynx receives cholinergic innervation from three types of pharyngeal motor neurons: M1, M2, and M5 [38]. Nicotine inhibited pharyngeal pumping by causing tetanic contraction of pharyngeal muscle [37]. Therefore, we hypothesized that clozapine or the biologically active clozapine metabolite N-desmethylclozapine [39] activated pharyngeal muscle ACR-7 channels, causing tetanus with consequent larval arrest. We further hypothesized that acr-7(tm863) and acr-7(RNAi) loss-of-function mutations blocked activation by clozapine and thereby suppressed pharyngeal paralysis and larval arrest.

Knockout of acr-7 suppressed clozapine-induced inhibition of pharyngeal pumping

Clozapine inhibited pharyngeal pumping of wild-type animals in a concentration-dependent manner. On average the pumping rate in the absence of clozapine was 112.7±1.4 pumps/20 sec, whereas the pumping rate in the presence of clozapine was 59.0±4.0 pumps/20 sec (160 µM), 34.4±3.7 pumps/20 sec (320 µM), and 16.8±2.5 pumps/20 sec (500 µM) (Figure 7B, P<0.0001, unpaired t-test). The pharyngeal pumping rate of acr-7(tm863) mutants was slightly decreased compared to wild type. The mean pumping rate of acr-7(tm863) mutants in the absence of drug was 103.1±1.2 pumps/20 sec (Figure 7B, P<0.05, unpaired t-test). That the acr-7(tm863) mutant displays a relatively normal pumping rate argues against a model in which acr-7 is required for pumping and clozapine inhibits this function. However, the acr-7(tm863) deletion suppressed clozapine-induced inhibition of pharyngeal pumping. While the mean pumping rate at 500 µM clozapine was 16.8±2.5 pumps/20 sec for N2 animals, the rate for acr-7(tm863) mutants was 40.9±2.9 pumps/20 sec (Figure 7B, P<0.0001, unpaired t-test). Compared to acr-7(tm863) mutants, acr-7(tm863) mchEx40 animals were partially rescued for this suppression with a mean pumping rate of 29.3±2.9 pumps/20 sec at 500 µM clozapine (Figure 7B, P<0.01, unpaired t-test).

In order to test whether ACR-7 acts specifically in pharyngeal muscle to affect pumping, we generated transgenic lines expressing Pmyo-2::acr-7 or Pmyo-2::acr-7::GFP translational fusion constructs. myo-2 encodes a myosin heavy chain gene expressed exclusively in pharyngeal muscle. acr-7(tm863) mchEx207 animals, expressing the Pmyo-2::acr-7 transgene, were rescued for suppression of clozapine-induced inhibition of pharyngeal pumping with a mean pumping rate of 17.3±1.4 pumps/20 sec at 500 µM clozapine (Figure 7B, P<0.001, unpaired t-test). acr-7(tm863) mchEx207 animals were also rescued for suppression of clozapine-induced developmental delay (Figure 4A). acr-7(tm863) mchEx211 animals, expressing the Pmyo-2::acr-7::GFP transgene, displayed strong fluorescence in the pharyngeal muscles and were rescued for both the pharyngeal pumping and developmental phenotypes. Thus, acr-7 was required in pharyngeal muscle for clozapine-induced inhibition of pharyngeal pumping and for clozapine-induced developmental delay.

Nicotine and levamisole phenocopied clozapine's inhibition of pharyngeal pumping. The mean pumping rate of N2 animals was 58.1±2.9 pumps/20 sec in 2 mM nicotine (Figure 7C, P<0.0001, unpaired t-test) and 0.0 pumps/20 sec in 300 µM levamisole (data not shown). d-TC alone did not change the pumping rate in wild-type animals, similar to the relatively normal pharyngeal pumping rate seen with acr-7 knockout. However, d-TC did block inhibition of pharyngeal pumping by either clozapine or nicotine. The mean pumping rate of wild-type animals in 500 µM clozapine was 25.3±3.1 pumps/20 sec (Figure 7C, P<0.0001, unpaired t-test), compared to 69.5±4.9 pumps/20 sec with co-application of 500 µM d-TC (Figure 7C, P<0.0001, unpaired t-test). The mean pumping rate of wild-type animals in 2 mM nicotine was significantly increased to 68.5±3.7 pumps/20 sec with co-application of 500 µM d-TC, compared to wild-type animals in 2 mM nicotine alone (Figure 7C, P<0.05, unpaired t-test). However, d-TC failed to block the residual inhibition of pharyngeal pumping produced by either clozapine or nicotine in acr-7(tm863) mutants, indicating that acr-7 knockout occludes the effect of d-TC (Figure 7D). These results suggested that clozapine and nicotine inhibit pharyngeal pumping, in part, by activating ACR-7 receptors in the pharynx.


Clozapine exposure during adulthood modulates several C. elegans behaviors, such as enhancement of egg-laying [11] and inhibition of pharyngeal pumping [12], [19] and locomotion. In addition, clozapine exposure during early development produces larval arrest in C. elegans [12], [20], an effect that may relate to human developmental abnormalities associated with clozapine treatment during pregnancy [20], [40]. High drug concentrations are required for penetration of the C. elegans cuticle [41], but we used HPLC to show that clozapine levels required to produce larval arrest in C. elegans (∼18 µg/ml) [12] are close to those expected in brains of human patients treated with clozapine (∼11 µg/ml) [42], [43]. We employed clozapine-induced developmental delay to perform a genome-wide RNAi screen in C. elegans for scla genes and identified 40 candidate suppressors of clozapine-induced larval arrest. Several suppressors, such as magi-1, lin-12, and ina-1, have human orthologs implicated in the pathogenesis of schizophrenia but have not been previously shown to mediate the biological effects of an APD [44][46].

The molecular mechanisms of action of human disease genes underlying psychotic disorders are largely unclear. The identification of candidate APD targets in a genetic model organism with a nervous system afforded us the opportunity to analyze the mechanism of action of one such target in detail. However, elucidating the mechanisms underlying APD modulation of ACR-7 cannot fully explain the effects of APDs on C. elegans. Several lines of evidence indicate that clozapine-induced larval arrest involves multiple genetic pathways. First, the number and diversity of suppressors to emerge from our screen suggest that they may not constitute a single pathway. Second, clozapine's developmental and behavioral effects in C. elegans are partially, not fully, suppressed by acr-7(lf) (Figure 4A and Figure 7B). Third, other pathways, such as the insulin signaling pathway, are known to be involved [11], [12], [14]. Previously, we used a candidate gene approach to show that mutations in the C. elegans insulin/IGF receptor ortholog daf-2 and in its downstream effector the phosphatidyl inositol 3-kinase (PI3K) age-1 suppressed clozapine-induced larval arrest. Subsequent work confirmed the discovery that clozapine activates insulin signaling in C. elegans and showed that other APDs do so as well [13], [14]. Of note, acr-7 and age-1 may act in concert to mediate APD effects in C. elegans, since the α7-nAChR has been shown to transduce signals to PI3K via direct physical association in rat cortical cultures [47]. Fourth, clozapine has moderate-to-high affinity for many neurotransmitter receptors, and its complex pharmacology may well underlie its clinical superiority. Indeed, ‘selectively non-selective’ drugs or ‘magic shotguns’ with affinity for multiple specific targets with synergistic effects may prove to be more effective medications for the treatment of schizophrenia than selective drugs (‘magic bullets’) that hit one target [5]. Therefore, it will be important to understand not only how nAChR homologs might mediate therapeutic or toxic effects of clozapine, but also how other suppressors might do so. With this end in mind, detailed characterization of several other suppressors is now underway in our laboratory. These studies might provide evidence on how different actions of clozapine interact.

We would also like to know whether particular suppressors mediate clozapine-specific effects or mediate APD effects more generally. To address the question of specificity will require identifying the cellular and molecular mechanisms of suppression for particular mutants and then testing the relevance of those mechanisms for APDs other than clozapine. If the role of a suppressor is clozapine-specific, that target may help explain clozapine's unique therapeutic or toxic effects. If the role is not clozapine-specific, that target may help identify novel mechanisms of action of APDs in general. Importantly then, further characterization of suppressors from our screen may advance the field whether suppression is a clozapine-specific effect or is a characteristic of APDs in general.

Although some RNAi suppressors may act indirectly, some may have human homologs that directly mediate either therapeutic or toxic effects of clozapine. Based on the fact that cha-1(lf) and unc-17(lf) alleles failed to suppress clozapine-induced larval arrest, we hypothesized that clozapine does not stimulate Ach release, but rather that clozapine modulates ACR-7 directly. Particularly in whole-organism studies, direct effects can be pharmacologically complex, involving activation, inhibition, or a combination of the two. For instance, clozapine acts as an agonist at the human muscarinic M1 receptor, while its biologically active metabolite, N-desmethylclozapine, acts as an antagonist [39], [48]. Such pharmacological complexity is relevant in the case of nAChRs specifically, where, for example, addition of a methyl group at the amine moiety of cocaine changes that drug's profile from noncompetitive antagonist to agonist [49]. To clarify the mechanism whereby clozapine modulates ACR-7, we undertook a series of genetic, pharmacological, developmental, and behavioral studies in C. elegans.

We showed that that acr-7 mutants suppressed clozapine-induced developmental delay and that a full-length translational Pacr-7::acr-7::GFP fusion construct rescued this effect. acr-7 was strongly expressed in the C. elegans pharynx, and acr-7 knockout suppressed clozapine-induced inhibition of pharyngeal pumping. Furthermore, a translational Pmyo-2::acr-7 fusion construct rescued suppression of the developmental delay and pharyngeal pumping phenotypes, indicating that ACR-7 acts specifically in pharyngeal muscle cells to mediate these phenotypes. These results suggested that clozapine activates ACR-7 to inhibit pharyngeal pumping and, thereby, produce larval arrest. Consistent with this model, nAChR agonists phenocopied both the developmental and behavioral effects of clozapine. Similarly, nicotine-induced developmental delay required acr-7. However, acr-7(tm863) did not block nicotine-induced inhibition of pharyngeal pumping, suggesting that nicotine may act through multiple nAChRs to inhibit pharyngeal pumping (Figure 7C and 7D).

Also consistent with our model, nAChR antagonists suppressed clozapine-induced developmental delay and clozapine-induced inhibition of pharyngeal pumping. The results indicated that, as predicted on the basis of sequence information, acr-7 encodes a nAChR. Suppression of the effects of nicotine and clozapine on pharyngeal pumping and development are the first phenotypes to be identified in acr-7 mutants [34]. As noted above, clozapine's effects at the whole-organism level may be pharmacologically complex, involving activation, inhibition, or both, but the simplest model to explain our results is that clozapine activates ACR-7. Thus, our data pointed to a novel finding - the existence of nAChRs that are activated by clozapine and/or the biologically active clozapine metabolite N-desmethylclozapine [39].

A wealth of evidence has implicated nAChR expression and function in general, and the α7-nAChR in particular, in the pathogenesis of schizophrenia [15][17], [50], a psychotic disorder for which clozapine appears to be the most effective medication [2][4]. First, decreased nAChR expression has been reported in a number of brain regions of schizophrenics [51][54]. Second, schizophrenics smoke more frequently than the general population, and nicotine exposure has been shown to improve cognition in animals and humans. Therefore, increased smoking in schizophrenics may represent an attempt to self-medicate for cognitive deficits associated with the disease [50]. Third, genetic studies have linked the human α7-nAChR gene (CHRNA7) to defective gating of the P50 auditory evoked response, which is related to attentional abnormalities in schizophrenia [17]. Finally, α7-nAChR agonists are currently in development for the treatment of psychosis, although no known APDs have been demonstrated to act by this mechanism [16].

Previous reports have suggested that clozapine inhibits the function of α7-nAChRs [55], [56]. However, inhibition may be specific to the background of the receptor or to species-specific sequence differences [29], [57], [58]. Moreover, our RNAi screen was designed to identify targets activated by clozapine, since we screened for suppression of the drug's effects by gene knockdown. Interestingly, clozapine improved a schizophrenia-like endophenotype in mice via stimulation of α7-nAChRs, although this effect was hypothesized to be indirect [59].

C. elegans has at least 29 different nAChR subunits grouped into five subfamilies based on homology: DEG-3-like, UNC-38-like, ACR-8-like, UNC-29-like, and ACR-16-like nAChRs [28], [29]. ACR-7 is a member of the ACR-16-like group of nAChR subunits, a group that shows homology to the vertebrate α7-10 nAChRs [28], [29]. Importantly, we do not know which human α-like subunit is the ACR-7 ortholog. For example, although acr-16 showed homology to the vertebrate α7-10 nAChRs, a mouse α4β2 nAChR transgene driven by the acr-16 promoter rescued nicotine-dependent behaviors in the acr-16 mutant background, while a mouse α7 nAChR transgene did not [60].

Mammals have at least 17 different nAChR subunits [28], [30], and these nAChRs may assemble in a wide variety of functional combinations [31], [61]. Of these, nine different α-nAChR subunits have been cloned from mammalian tissues to date and have been shown to form homopentamers or heteropentamers [30], [61]. Effects of APDs on the spectrum of nAChR subunit combinations have not been tested [62][65]. Therefore, whether APDs can activate one or more of these receptors is an important question, and finding such an interaction would constitute an important breakthrough in APD drug development.

In summary, we conducted the first genetic suppressor screen for APD targets in an animal. We then used the experimental advantages of C. elegans neurobiology and neurogenetics to delineate the novel molecular mechanism of action of a specific APD target. α-like nAChR signaling is a mechanism through which clozapine may produce its therapeutic and/or toxic effects in humans. This project was designed to translate basic findings in C. elegans into clinical applications. Identification of new mechanisms underlying the actions of APDs may lead to changes in both concepts and better-targeted treatments in psychiatric neurobiology.

Materials and Methods


We used the C. elegans Bristol strain N2 as the wild-type parent of our mutant strains and grew nematodes under standard culture conditions. Strains were maintained at 20°C. The mutant strains used in our experiments are provided in Table S1. The age-1(hx546) II mutation in strain TJ1052 had been backcrossed to the N2 strain three times, and we performed another three backcrosses to generate strain EAB100. The presence of the mutation was followed by restriction digest and confirmed by DNA sequencing. We backcrossed the following mutations to the N2 strain six times to generate strains: EAB1 sms-1(ok2399) IV, EAB101 scla-1(tm4806) IV, EAB102 scla-1(tm4534) IV, EAB103 ins-22(ok3616) III, EAB200 acr-7(tm863) II, and EAB201 acr-16(ok789) V from strains RB1854, F22B3.8(tm4806), F22B3.8(tm4534), RB2594, FX863, and RB918, respectively. The presence of the deletions was followed by PCR.

RNAi screen

We employed an RNAi feeding library (Geneservice Ltd), constructed by J. Ahringer's laboratory at the The Wellcome CRC Institute, University of Cambridge, Cambridge, England, to carry out a genome-wide screen in liquid culture for suppressors of clozapine-induced larval arrest [21]. Our protocol for feeding RNAi bacteria to animals in liquid culture was adapted from Nollen et al. (2004) [66]. Each RNAi culture was grown overnight at 37°C in 500 µl of LB with 100 µg/ml of ampicillin. The cultures were induced for four hours the following day by adding 1 ml of LB containing 100 µg/ml ampicillin and 1 mM isopropylthiogalactoside (IPTG) in a 37°C incubator. We transferred 200 µl of the induced cultures to 96-well plates and centrifuged them at 3000 rpm for 2 minutes. The supernatant was removed, and the induced bacterial pellet was resuspended in 100 µl of S-Basal. We then added 50 µl of solution containing S-Basal, 50 µg/ml ampicillin, 1 mM IPTG, and ∼3–5 synchronized L1 rrf-3 animals. These animals were maintained in liquid culture at 20°C on a rotating platform for three days until they reached young adulthood. We then added 1.5 µl of clozapine stock solution (20 mg/ml clozapine powder from Sigma-Aldrich #C6305 in 100% ethanol) to each well for a final concentration of 200 µg/ml (∼600 µM) clozapine. Progeny were scored for suppression of clozapine-induced larval arrest on day 8 (Figure 1A). Wells containing progeny that had developed to the L4 stage or beyond were scored as positives (Figure 1B). Those wells lacking progeny or containing contamination were retested. Each set included wells with dpy-6 RNAi in the absence of clozapine and blank wells in the presence of clozapine as controls.

Positive wells from the genome-wide RNAi screen in liquid culture were tested in triplicate using feeding RNAi on plates containing Nematode Growth Medium (NGM). Each set included triplicate wells of dpy-6 RNAi and unc-44 RNAi with and without clozapine as controls. Those wells lacking progeny, lacking a lawn, or containing contamination were retested. Mutants that produced suppression in at least 2/3 wells were taken to be positives, and the strength of suppression was scored: weak (+) - few progeny escaped larval arrest, medium (++) - ∼25% of progeny escaped larval arrest, robust (+++) - most progeny escaped larval arrest, NA - not scored (Table 1). The identity of triplicate positives was verified by sequencing plasmid DNA (MGH DNA Sequencing Core) using primer M13 (Integrated DNA Technologies, Inc.) and then blasting those sequences against the C. elegans genome using Wormbase BLAT. Triplicate positives without preexisting gene names and validated by knockout testing were assigned to the new gene name class scla for Suppressor of Clozapine-induced Larval Arrest.

Plasmid constructions

To generate a Pacr-7::GFP transcriptional fusion construct, we PCR-amplified the putative promoter region, including 1.3-kb upstream of the acr-7 gene, using DNA prepared from adult animals and using primers listed in Table S2. This clone was digested with PstI and XmaI restriction enzymes and ligated into the GFP vector pPD95.75. To generate a Pacr-7::acr-7::GFP translational fusion construct, we PCR-amplified the same acr-7 promoter sequence along with 4.3-kb of acr-7 genomic sequence, omitting the native stop codon, using DNA prepared from adult animals and using primers listed in Table S2. This clone was digested with PstI and KpnI restriction enzymes, sub-electroporated into pCR-XL-TOPO (Invitrogen, Cat: K4700-10), and then subcloned into pPD95.75. PCR was performed using PrimeSTAR HS DNA Polymerase (Takara Bio Inc.). GFP vector pPD95.75 was obtained from the Fire Lab C. elegans Vector Kit (Addgene).

To generate the Pmyo-2::acr-7 and Pmyo-2::acr-7::GFP translational fusion constructs, RNA was isolated from mixed-stage worms, and acr-7 cDNA was obtained using SuperScript III First-Strand Synthesis System (Invitrogen) with primers listed in Table S2. We then cloned the cDNA into Fire Lab vectors L2531 or L3790 (Addgene) using NheI and KpnI restriction enzymes or SalI and EagI restriction enzymes respectively. These Pmyo-2 constructs were injected into EAB200 animals using the same protocol described below for injection of the Pacr-7::acr-7::GFP construct.

All plasmid constructions were confirmed by sequencing (MGH DNA Sequencing Core).

Expression analysis

We generated extrachromosomal transgenic strains by microinjecting DNA into the gonads of young adult animals as described [67]. The Pacr-7::GFP construct was injected at 25 ng/µl along with the rol-6(su1006) marker (pRF4) at 50 ng/µl into N2 animals. The Pacr-7::acr-7::GFP construct was injected at 25 ng/µl along with the Pmyo-3::DsRed2 marker (pHC183; a gift from Antony Jose of the Hunter laboratory) at 40 ng/µl into EAB200 animals. Three to four independent extrachromosomal lines were generated for both the Pacr-7::GFP and Pacr-7::acr-7::GFP constructs. ACR-7::GFP expression shown here was studied in the EAB40 strain, but similar results were obtained in studies of the EAB20 - 24, EAB39, and EAB41 strains. Animals were placed on a 2% agarose pad on a slide in M9 with 50 mM sodium azide, then covered with a slip and studied by DIC and fluorescence microscopy using a Zeiss Axio Image A1 microscope. Photographs were taken using a 40× objective on a confocal laser microscope (Leica TCS, Germany).

Developmental assays

Experiments were performed using Falcon 12-well plates (Becton Dickinson) containing OP50 bacteria on NGM. Clozapine, nicotine, levamisole, DHβE, and d-TC were purchased from Sigma-Aldrich. Olanzapine was purchased from Waterstone Technology. Stock solutions of each drug were prepared in DMSO and then diluted 1∶1000 in water with acetic acid (1∶10,000). These diluted solutions were then pipetted onto the agar surrounding the bacterial lawn for final drug concentrations of 40, 80, 160, or 320 µM (0.1% DMSO), and the plates were left to dry overnight. On the next day, ∼30 synchronized L1 larvae were loaded into each well. Animals were then scored as L1, L2, L3, L4, young adult, or gravid adult at 24, 48, 72, 96 hours.

For stressor experiments, paraquat dichloride, tunicamycin, and DL-Dithiothreitol (DTT) were purchased from Sigma-Aldrich, and sodium dodecyl sulfate (SDS) was purchased from Fisher Scientific. Stock solutions of 10% SDS, 2 M paraquat, or 0.2 M DTT in water or 2.5 mg/ml tunicamycin in DMSO were diluted in M9 and pipetted onto the agar to achieve a range of drug concentrations. On the next day, 5–10 adult animals were placed in each well of a 12-well plate. Adults were allowed to lay 25–50 eggs and then removed. Plates were scored for developmental delay and lethality each day until the next generation hatched or until all animals died.

Pharyngeal pumping assays

Drug plates were prepared as described above. Synchronized L1 larvae were grown to the L4 stage and picked 24 hours in advance of the experiments. Five adult animals were transferred into drug wells or control wells (0.1% DMSO alone). Two hours later, the number of pumps during 20 seconds was scored. Only animals on the bacterial lawn were scored.

Statistical analysis

Data were expressed as means ± S.E.M. Statistical comparisons were performed using the unpaired, two-tailed Student's t-test and one-way ANOVA test where appropriate.

Supporting Information

Figure S1.

RNAi screen mutants did not suppress stressor-induced developmental delay. (A) Developmental delay seen with SDS or paraquat after 24 hours. (B) Developmental delay seen with SDS or paraquat after 48 hours. For control conditions, vehicle alone was applied to the agar. Paraquat at 0.5 mM produced significant lethality at 48 hours (data not shown).



Table S1.

List of mutant strains used in these studies. Dr. L. Chen (University of Minnesota, Minneapolis, MN) provided LH202. Dr. C. Hunter (Harvard University, Cambridge, MA) provided NL4256. Dr. Y. Jin (UCSD, La Jolla, CA) provided CZ9957. Dr. S. Mitani (NBP-Japan) provided F22B3.8(tm4806) IV and F22B3.8(tm4534) IV. All other strains used in this work, except strains EAB1 through EAB211, were provided by the Caenorhabditis Genetics Center, which is funded by the NIH National Center for Research Resources (NCRR). NA, not available.



Table S2.

List of primers used for plasmid constructions.




We thank Buttner lab members for advice and discussions, and Theresa Stiernagle at the C. elegans Genetic Center and the National BioResource Project (Tokyo, Japan) for strains used in this work. We thank Drs. Michael M. Francis, Hilary Prescott, and Navonil Banerjee in the Department of Neurobiology at University of Massachusetts Medical School for assistance with two-electrode voltage-clamp recordings of Xenopus laevis oocytes and Drs. David Clapham and Longjun Wu in the Department of Neurobiology at Harvard Medical School and the Howard Hughes Medical Institute for assistance with whole-cell voltage-clamp recordings of cultured HEK293T and PC12 cells.

Author Contributions

Conceived and designed the experiments: TS LH XW BMC EAB. Performed the experiments: TS SED AO GRS LH XW EAB. Analyzed the data: TS SED AO GRS LH XW EAB. Wrote the paper: TS AO LH XW BMC EAB.


  1. 1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1223. doi: 10.1056/nejmoa051688
  2. 2. Agid O, Foussias G, Singh S, Remington G (2010) Where to position clozapine: re examining the evidence. Can J Psychiatry 55: 677–684.
  3. 3. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610. doi: 10.1176/appi.ajp.163.4.600
  4. 4. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, et al. (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60: 82–91. doi: 10.1001/archpsyc.60.1.82
  5. 5. Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12: 904–922. doi: 10.1038/
  6. 6. Meltzer HY (2004) What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 4: 53–57. doi: 10.1016/j.coph.2003.09.010
  7. 7. Dranovsky A, Hen R (2006) Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 59: 1136–1143. doi: 10.1016/j.biopsych.2006.03.082
  8. 8. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805–809. doi: 10.1126/science.1083328
  9. 9. Burne T, Scott E, van Swinderen B, Hilliard M, Reinhard J, et al. (2011) Big ideas for small brains: what can psychiatry learn from worms, flies, bees and fish? Mol Psychiatry 16: 7–16. doi: 10.1038/mp.2010.35
  10. 10. Wang X, Sliwoski GR, Buttner EA (2011) The relevance of Caenorhabditis elegans genetics for understanding human psychiatric disease. Harv Rev Psychiatry 19: 210–218. doi: 10.3109/10673229.2011.599185
  11. 11. Karmacharya R, Lynn SK, Demarco S, Ortiz A, Wang X, et al. (2011) Behavioral effects of clozapine: involvement of trace amine pathways in C. elegans and M. musculus. Brain Res 1393: 91–99. doi: 10.1016/j.brainres.2011.04.010
  12. 12. Karmacharya R, Sliwoski GR, Lundy MY, Suckow RF, Cohen BM, et al. (2009) Clozapine interaction with phosphatidyl inositol 3-kinase (PI3K)/insulin-signaling pathway in Caenorhabditis elegans. Neuropsychopharmacology 34: 1968–1978. doi: 10.1038/npp.2009.35
  13. 13. Weeks KR, Dwyer DS, Aamodt EJ (2011) Clozapine and lithium require Caenorhabditis elegans beta-arrestin and serum- and glucocorticoid-inducible kinase to affect Daf-16 (FOXO) localization. J Neurosci Res 89: 1658–1665. doi: 10.1002/jnr.22705
  14. 14. Weeks KR, Dwyer DS, Aamodt EJ (2010) Antipsychotic drugs activate the C. elegans Akt pathway via the DAF-2 insulin/IGF-1 receptor. ACS Chem Neurosci 1: 463–473. doi: 10.1021/cn100010p
  15. 15. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40–68. doi: 10.1038/
  16. 16. Jones CK, Byun N, Bubser M (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37: 16–42. doi: 10.1038/npp.2011.199
  17. 17. Martin LF, Freedman R (2007) Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 78: 225–246. doi: 10.1016/s0074-7742(06)78008-4
  18. 18. Ericson E, Gebbia M, Heisler LE, Wildenhain J, Tyers M, et al. (2008) Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet 4: e1000151 doi:10.1371/journal.pgen.1000151.
  19. 19. Donohoe DR, Jarvis RA, Weeks K, Aamodt EJ, Dwyer DS (2009) Behavioral adaptation in C. elegans produced by antipsychotic drugs requires serotonin and is associated with calcium signaling and calcineurin inhibition. Neurosci Res 64: 280–289. doi: 10.1016/j.neures.2009.03.012
  20. 20. Donohoe DR, Aamodt EJ, Osborn E, Dwyer DS (2006) Antipsychotic drugs disrupt normal development in Caenorhabditis elegans via additional mechanisms besides dopamine and serotonin receptors. Pharmacol Res 54: 361–372. doi: 10.1016/j.phrs.2006.07.002
  21. 21. Kamath RS, Ahringer J (2003) Genome-wide RNAi screening in Caenorhabditis elegans. Methods 30: 313–321. doi: 10.1016/s1046-2023(03)00050-1
  22. 22. Simmer F, Moorman C, van der Linden AM, Kuijk E, van den Berghe PV, et al. (2003) Genome-wide RNAi of C. elegans using the hypersensitive rrf-3 strain reveals novel gene functions. PLoS Biol 1: e12 doi:10.1371/journal.pbio.0000012.
  23. 23. Harada H, Kurauchi M, Hayashi R, Eki T (2007) Shortened lifespan of nematode Caenorhabditis elegans after prolonged exposure to heavy metals and detergents. Ecotoxicol Environ Saf 66: 378–383. doi: 10.1016/j.ecoenv.2006.02.017
  24. 24. Kondo M, Yanase S, Ishii T, Hartman PS, Matsumoto K, et al. (2005) The p38 signal transduction pathway participates in the oxidative stress-mediated translocation of DAF-16 to Caenorhabditis elegans nuclei. Mech Ageing Dev 126: 642–647. doi: 10.1016/j.mad.2004.11.012
  25. 25. Lee W, Lee TH, Park BJ, Chang JW, Yu JR, et al. (2005) Caenorhabditis elegans calnexin is N-glycosylated and required for stress response. Biochem Biophys Res Commun 338: 1018–1030. doi: 10.1016/j.bbrc.2006.01.017
  26. 26. Struwe WB, Hughes BL, Osborn DW, Boudreau ED, Shaw KM, et al. (2009) Modeling a congenital disorder of glycosylation type I in C. elegans: a genome-wide RNAi screen for N-glycosylation-dependent loci. Glycobiology 19: 1554–1562. doi: 10.1093/glycob/cwp136
  27. 27. Kamath RS, Fraser AG, Dong Y, Poulin G, Durbin R, et al. (2003) Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421: 231–237. doi: 10.1038/nature01278
  28. 28. Jones AK, Davis P, Hodgkin J, Sattelle DB (2007) The nicotinic acetylcholine receptor gene family of the nematode Caenorhabditis elegans: an update on nomenclature. Invert Neurosci 7: 129–131. doi: 10.1007/s10158-007-0049-z
  29. 29. Jones AK, Sattelle DB (2004) Functional genomics of the nicotinic acetylcholine receptor gene family of the nematode, Caenorhabditis elegans. Bioessays 26: 39–49. doi: 10.1002/bies.10377
  30. 30. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89: 73–120. doi: 10.1152/physrev.00015.2008
  31. 31. Fucile S (2004) Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 35: 1–8. doi: 10.1016/j.ceca.2003.08.006
  32. 32. Boulin T, Gielen M, Richmond JE, Williams DC, Paoletti P, et al. (2008) Eight genes are required for functional reconstitution of the Caenorhabditis elegans levamisole sensitive acetylcholine receptor. Proc Natl Acad Sci U S A 105: 18590–18595. doi: 10.1073/pnas.0806933105
  33. 33. Jospin M, Qi YB, Stawicki TM, Boulin T, Schuske KR, et al. (2009) A neuronal acetylcholine receptor regulates the balance of muscle excitation and inhibition in Caenorhabditis elegans. PLoS Biol 7: e1000265 doi:10.1371/journal.pbio.1000265.
  34. 34. Community TCeR (2011) Wormbase web site, release WS227.
  35. 35. Alfonso A, Grundahl K, Duerr JS, Han HP, Rand JB (1993) The Caenorhabditis elegans unc-17 gene: a putative vesicular acetylcholine transporter. Science 261: 617–619. doi: 10.1126/science.8342028
  36. 36. Rand JB, Russell RL (1984) Choline acetyltransferase-deficient mutants of the nematode Caenorhabditis elegans. Genetics 106: 227–248.
  37. 37. Raizen DM, Lee RY, Avery L (1995) Interacting genes required for pharyngeal excitation by motor neuron MC in Caenorhabditis elegans. Genetics 141: 1365–1382.
  38. 38. Rand JB (2007) Wormbook: Acetylcholine. doi: 10.1895/wormbook.1.131.1
  39. 39. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, et al. (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A 100: 13674–13679. doi: 10.1073/pnas.1835612100
  40. 40. Costa LG, Steardo L, Cuomo V (2004) Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects. Pharmacol Rev 56: 103–147. doi: 10.1124/pr.56.1.5
  41. 41. Page AP, Johnstone IL (2007) Wormbook: The cuticle. doi: 10.1895/wormbook.1.138.1
  42. 42. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, et al. (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9: 117–124. doi: 10.1038/npp.1993.50
  43. 43. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, et al. (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153: 820–822.
  44. 44. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, et al. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320: 539–543. doi: 10.1126/science.1155174
  45. 45. Walsh MT, Ryan M, Hillmann A, Condren R, Kenny D, et al. (2002) Elevated expression of integrin alpha(IIb) beta(IIIa) in drug-naive, first-episode schizophrenic patients. Biol Psychiatry 52: 874–879. doi: 10.1016/s0006-3223(02)01400-2
  46. 46. Wang Z, Wei J, Zhang X, Guo Y, Xu Q, et al. (2006) A review and re-evaluation of an association between the NOTCH4 locus and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 141B: 902–906. doi: 10.1002/ajmg.b.30383
  47. 47. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, et al. (2001) alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta amyloid-induced neurotoxicity. J Biol Chem 276: 13541–13546.
  48. 48. Thomas DR, Dada A, Jones GA, Deisz RA, Gigout S, et al. (2010) N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor. Neuropharmacology 58: 1206–1214. doi: 10.1016/j.neuropharm.2010.02.017
  49. 49. Francis MM, Cheng EY, Weiland GA, Oswald RE (2001) Specific activation of the alpha 7 nicotinic acetylcholine receptor by a quaternary analog of cocaine. Mol Pharmacol 60: 71–79.
  50. 50. Mobascher A, Winterer G (2008) The molecular and cellular neurobiology of nicotine abuse in schizophrenia. Pharmacopsychiatry 41Suppl 1: S51–59. doi: 10.1055/s-2008-1081463
  51. 51. Freedman R, Adams CE, Leonard S (2000) The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat 20: 299–306. doi: 10.1016/s0891-0618(00)00109-5
  52. 52. Freedman R, Hall M, Adler LE, Leonard S (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22–33. doi: 10.1016/0006-3223(94)00252-x
  53. 53. Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, et al. (2003) Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 54: 1222–1233. doi: 10.1016/s0006-3223(03)00348-2
  54. 54. Marutle A, Zhang X, Court J, Piggott M, Johnson M, et al. (2001) Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22: 115–126. doi: 10.1016/s0891-0618(01)00117-x
  55. 55. Grinevich VP, Papke RL, Lippiello PM, Bencherif M (2009) Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology 57: 183–191. doi: 10.1016/j.neuropharm.2009.05.003
  56. 56. Singhal SK, Zhang L, Morales M, Oz M (2007) Antipsychotic clozapine inhibits the function of alpha7-nicotinic acetylcholine receptors. Neuropharmacology 52: 387–394. doi: 10.1016/j.neuropharm.2006.08.023
  57. 57. Ballivet M, Alliod C, Bertrand S, Bertrand D (1996) Nicotinic acetylcholine receptors in the nematode Caenorhabditis elegans. J Mol Biol 258: 261–269. doi: 10.1006/jmbi.1996.0248
  58. 58. Raymond V, Mongan NP, Sattelle DB (2000) Anthelmintic actions on homomer forming nicotinic acetylcholine receptor subunits: chicken alpha7 and ACR-16 from the nematode Caenorhabditis elegans. Neuroscience 101: 785–791. doi: 10.1016/s0306-4522(00)00279-7
  59. 59. Simosky JK, Stevens KE, Adler LE, Freedman R (2003) Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl) 165: 386–396.
  60. 60. Feng Z, Li W, Ward A, Piggott BJ, Larkspur ER, et al. (2006) A C. elegans model of nicotine-dependent behavior: regulation by TRP-family channels. Cell 127: 621–633. doi: 10.1016/j.cell.2006.09.035
  61. 61. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, et al. (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 78: 703–711. doi: 10.1016/j.bcp.2009.05.024
  62. 62. Wang N, Orr-Urtreger A, Chapman J, Ergun Y, Rabinowitz R, et al. (2005) Hidden function of neuronal nicotinic acetylcholine receptor beta2 subunits in ganglionic transmission: comparison to alpha5 and beta4 subunits. J Neurol Sci 228: 167–177. doi: 10.1016/j.jns.2004.11.050
  63. 63. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, et al. (1996) Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. J Biol Chem 271: 17656–17665. doi: 10.1074/jbc.271.30.17656
  64. 64. Yu CR, Role LW (1998) Functional contribution of the alpha5 subunit to neuronal nicotinic channels expressed by chick sympathetic ganglion neurones. J Physiol 509 (Pt 3) 667–681. doi: 10.1111/j.1469-7793.1998.667bm.x
  65. 65. Yu CR, Role LW (1998) Functional contribution of the alpha7 subunit to multiple subtypes of nicotinic receptors in embryonic chick sympathetic neurones. J Physiol 509 (Pt 3) 651–665. doi: 10.1111/j.1469-7793.1998.651bm.x
  66. 66. Nollen EA, Garcia SM, van Haaften G, Kim S, Chavez A, et al. (2004) Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A 101: 6403–6408. doi: 10.1073/pnas.0307697101
  67. 67. Mello CC, Kramer JM, Stinchcomb D, Ambros V (1991) Efficient gene transfer in C.elegans: extrachromosomal maintenance and integration of transforming sequences. EMBO J 10: 3959–3970.